Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Net Income (2016 - 2025)

Historic Net Income for Cartesian Therapeutics (RNAC) over the last 11 years, with Q3 2025 value amounting to -$19.5 million.

  • Cartesian Therapeutics' Net Income fell 3010.27% to -$19.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$83.7 million, marking a year-over-year increase of 5991.61%. This contributed to the annual value of -$77.4 million for FY2024, which is 6476.08% up from last year.
  • Latest data reveals that Cartesian Therapeutics reported Net Income of -$19.5 million as of Q3 2025, which was down 3010.27% from -$20.1 million recorded in Q2 2025.
  • In the past 5 years, Cartesian Therapeutics' Net Income registered a high of $15.0 million during Q2 2024, and its lowest value of -$196.7 million during Q4 2023.
  • Its 5-year average for Net Income is -$17.4 million, with a median of -$12.2 million in 2024.
  • In the last 5 years, Cartesian Therapeutics' Net Income surged by 550566.8% in 2022 and then crashed by 343714.58% in 2023.
  • Quarter analysis of 5 years shows Cartesian Therapeutics' Net Income stood at $12.2 million in 2021, then plummeted by 51.85% to $5.9 million in 2022, then plummeted by 3437.15% to -$196.7 million in 2023, then surged by 87.66% to -$24.3 million in 2024, then rose by 19.6% to -$19.5 million in 2025.
  • Its Net Income stands at -$19.5 million for Q3 2025, versus -$20.1 million for Q2 2025 and -$19.9 million for Q1 2025.